Tesofensine vs Tirzepatide
A side-by-side research comparison of Tesofensine and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Tesofensine | Tirzepatide |
|---|---|---|
| Full name | Tesofensine (Triple Monoamine Reuptake Inhibitor) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | FDA Approved |
| Mechanism | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 329.4 Da | 4,814 Da |
| Half-life | 8-10 days | 5 days (120 hours) |
| Bioavailability | High (oral ~93%) | High (SubQ ~80%) |
| Typical dose | 0.25-0.5 mg | 2.5 mg → titrate up to 15 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral | Subcutaneous injection |
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.